{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field 8b77e6b8-86d5-486e-a8f0-b28e04bf9bd9 --><h2>Flucloxacillin</h2><!-- end field 8b77e6b8-86d5-486e-a8f0-b28e04bf9bd9 -->","summary":"","htmlStringContent":"<!-- begin item 8fba7ec0-3278-4a12-b0af-32dc7ec15eba --><!-- end item 8fba7ec0-3278-4a12-b0af-32dc7ec15eba -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"15b482f1-3aab-56d0-816e-cb815f7a4747","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4bd83657-7428-4406-b4eb-82447522ea4c --><h3>What are the contraindications and cautions for flucloxacillin?</h3><!-- end field 4bd83657-7428-4406-b4eb-82447522ea4c -->","summary":"","htmlStringContent":"<!-- begin item 27d9f952-f212-468d-ad38-063b7de93114 --><!-- begin field f7c94756-aecb-4273-8ae6-cc4319d0389b --><header> </header><ul><li><strong>Do not prescribe flucloxacillin</strong> to people with:<ul><li>A true penicillin allergy — gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin.</li><li>History of flucloxacillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution</strong> to people with: <ul><li>Hepatic dysfunction (not flucloxacillin-related), especially if they are 50 years of age or older, or have a serious underlying medical condition.</li><li>Severe renal impairment — reduce the dose if the person's estimated Glomerular Filtration Rate (eGFR) is less than 10 mL/minute/1.73 m<sup>2</sup>.</li></ul></li><li>Flucloxacillin may be used during pregnancy and breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field f7c94756-aecb-4273-8ae6-cc4319d0389b --><!-- end item 27d9f952-f212-468d-ad38-063b7de93114 -->","subChapters":[]},{"id":"f1e8154a-457c-5524-a870-7816be000720","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e91c073d-56e6-402b-b17b-f19853d939fd --><h3>What are the drug interactions of flucloxacillin?</h3><!-- end field e91c073d-56e6-402b-b17b-f19853d939fd -->","summary":"","htmlStringContent":"<!-- begin item 1d5e459c-d104-45a4-9c3a-1afa7b3dde97 --><!-- begin field abb6cddd-82dc-4e7a-aea3-71e7159f9e1b --><ul><li><strong>Drug interactions with flucloxacillin include:</strong><ul><li>Anticoagulants such as warfarin — consider monitoring the international normalized ratio (INR) and adjust the warfarin dose accordingly.</li><li>Methotrexate — flucloxacillin may reduce clearance of methotrexate and increase the risk of toxicity. Consider monitoring concurrent use. One recommendation is to carry out a twice-weekly platelet and white cell count for 2 weeks initially, and measure methotrexate levels if toxicity is suspected.</li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of flucloxacillin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field abb6cddd-82dc-4e7a-aea3-71e7159f9e1b --><!-- end item 1d5e459c-d104-45a4-9c3a-1afa7b3dde97 -->","subChapters":[]},{"id":"36b72d7b-f808-50d9-8a17-c5f43754fa8e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 57712a2c-08a6-4d54-b841-7075b67a46f5 --><h3>What are the adverse effects of flucloxacillin?</h3><!-- end field 57712a2c-08a6-4d54-b841-7075b67a46f5 -->","summary":"","htmlStringContent":"<!-- begin item adfda1dd-814f-4928-907f-570c140c19bc --><!-- begin field 38382dcd-cbf0-41f7-806f-be203b784ccc --><ul><li>Diarrhoea is a common adverse effect of flucloxacillin.</li><li>Cholestatic jaundice and hepatitis may occur (very rarely) up to several weeks after treatment with flucloxacillin has been stopped. Risk factors include treatment for more than 2 weeks, and increasing age.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field 38382dcd-cbf0-41f7-806f-be203b784ccc --><!-- end item adfda1dd-814f-4928-907f-570c140c19bc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}